Physician profile
Sarah E Dedrick
NPI 1306076336
$941.04
in general payments reported to CMS, 2019-2025
16 companies · $298 in 2025
The $298 reported for 2025 was more than what 85% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $51.29 · 2022: $131 · 2023: $155 · 2024: $307 · 2025: $298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $759.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $759.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $275.74 | 2022-2024 | Azstarys |
| Ironshore Pharmaceuticals INC. | $136.89 | 2024 | |
| Biomarin Pharmaceutical INC. | $112.68 | 2025 | Voxzogo 1.2mg |
| Sanofi-Aventis U.S. LLC | $91.46 | 2025 | |
| Pfizer INC. | $81.99 | 2023-2025 | |
| Cranial Technologies, INC | $64.90 | 2024-2025 | Doc Band |
| Sanofi Pasteur INC. | $36.97 | 2022-2025 | |
| Glaxosmithkline, LLC. | $29.25 | 2023-2025 | Pediarix, Bexsero, Penmenvy |
| Merck Sharp & Dohme LLC | $17.02 | 2022 | |
| Travere Therapeutics, INC. | $16.72 | 2023 | Cholbam |
| Neos Therapeutics, LP | $14.02 | 2021 | |
| Collegium Pharmaceutical, INC. | $13.56 | 2025 | Jornay Pm |
| Kaleo, INC. | $12.57 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.55 | 2021 | |
| Adlon Therapeutics L.P. | $12.51 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $12.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Dedrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.